BRPI0517438A - composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica - Google Patents

composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica

Info

Publication number
BRPI0517438A
BRPI0517438A BRPI0517438-4A BRPI0517438A BRPI0517438A BR PI0517438 A BRPI0517438 A BR PI0517438A BR PI0517438 A BRPI0517438 A BR PI0517438A BR PI0517438 A BRPI0517438 A BR PI0517438A
Authority
BR
Brazil
Prior art keywords
compound
muscarinic
treating
pharmaceutical composition
condition associated
Prior art date
Application number
BRPI0517438-4A
Other languages
English (en)
Inventor
Almudena Rubio Esteban
Darryl Wayne Hilliard
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0517438A publication Critical patent/BRPI0517438A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSTO, MéTODO PARA TRATAR A CONDIçãO ASSOCIADA COM ATIVIDADE DO RECEPTOR MUSCARIINICO M4, USO DO COMPOSTO, E, COMPOSIçãO FARMACêUTICA. A presente invenção diz respeito à potencializadores alostéricos seletivos da Fórmula (I): ou sais destes farmaceuticamente aceitáveis, para o tratamento de distúrbios associados com receptores muscarínicos M~ 4~.
BRPI0517438-4A 2004-10-25 2005-10-18 composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica BRPI0517438A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62178504P 2004-10-25 2004-10-25
PCT/US2005/037271 WO2006047124A1 (en) 2004-10-25 2005-10-18 Thienopyridines as allosteric potentiators of the m4 muscarinic receptor

Publications (1)

Publication Number Publication Date
BRPI0517438A true BRPI0517438A (pt) 2008-10-07

Family

ID=36021809

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517438-4A BRPI0517438A (pt) 2004-10-25 2005-10-18 composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica

Country Status (16)

Country Link
US (1) US8071776B2 (pt)
EP (1) EP1807434B1 (pt)
JP (1) JP4945453B2 (pt)
CN (1) CN100577666C (pt)
AT (1) ATE478876T1 (pt)
AU (1) AU2005299957B2 (pt)
BR (1) BRPI0517438A (pt)
CA (1) CA2583550C (pt)
CY (1) CY1111477T1 (pt)
DE (1) DE602005023197D1 (pt)
DK (1) DK1807434T3 (pt)
ES (1) ES2349416T3 (pt)
MX (1) MX2007004794A (pt)
PL (1) PL1807434T3 (pt)
PT (1) PT1807434E (pt)
WO (1) WO2006047124A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493481B2 (en) 2012-02-23 2016-11-15 Vanderbilt University Substituted 5-aminothieno[2,3—C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
WO2014035829A1 (en) * 2012-08-31 2014-03-06 Vanderbilt University Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators
EA201690089A1 (ru) 2013-06-11 2017-04-28 Латвийский Институт Органического Синтеза ТИЕНО[2,3-b]ПИРИДИНЫ КАК МОДУЛЯТОРЫ СОСТОЯНИЯ МНОЖЕСТВЕННОЙ ЛЕКАРСТВЕННОЙ УСТОЙЧИВОСТИ
US9637498B2 (en) 2013-08-23 2017-05-02 Vanderbilt University Substituted thieno[2,3-C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
EP3394061B1 (en) 2015-12-23 2020-03-11 Merck Sharp & Dohme Corp. 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor
KR102474326B1 (ko) 2016-06-22 2022-12-05 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제
PL3478679T3 (pl) 2016-07-01 2021-10-25 Pfizer Inc. Pochodne 5,7-dihydro-pirolopirydyny do leczenia chorób neurologicznych i neurodegeneracyjnych
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
JP7097623B2 (ja) * 2016-11-07 2022-07-08 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
EP3534901B1 (en) 2016-11-07 2022-06-22 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
EP3558309B1 (en) 2016-11-07 2023-07-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
FI3642202T3 (fi) 2017-06-22 2023-03-01 Dihydro-pyrrolo-pyridiinijohdannaisia
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
WO2019113174A1 (en) 2017-12-05 2019-06-13 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2025201078A1 (zh) * 2024-03-25 2025-10-02 四川科伦药物研究院有限公司 化合物、包含其的药物组合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3430284A1 (de) * 1984-08-17 1986-02-27 Troponwerke GmbH & Co KG, 5000 Köln Neue tryptamin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung
MX9700696A (es) * 1994-07-27 1997-04-30 Sankyo Co Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos.
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
GB9924962D0 (en) * 1999-10-21 1999-12-22 Mrc Collaborative Centre Allosteric sites on muscarinic receptors
TWI310035B (en) * 2000-04-28 2009-05-21 Acadia Pharm Inc Muscarinic agonists
MXPA04007083A (es) * 2002-02-20 2004-10-29 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
US6974870B2 (en) * 2002-06-06 2005-12-13 Boehringer Ingelheim Phamaceuticals, Inc. Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses

Also Published As

Publication number Publication date
DE602005023197D1 (de) 2010-10-07
US8071776B2 (en) 2011-12-06
ES2349416T3 (es) 2011-01-03
CN100577666C (zh) 2010-01-06
CA2583550C (en) 2013-05-14
EP1807434A1 (en) 2007-07-18
PT1807434E (pt) 2010-09-22
MX2007004794A (es) 2007-07-09
CY1111477T1 (el) 2015-08-05
AU2005299957B2 (en) 2011-04-21
CN101048413A (zh) 2007-10-03
JP2008517913A (ja) 2008-05-29
AU2005299957A1 (en) 2006-05-04
PL1807434T3 (pl) 2011-02-28
JP4945453B2 (ja) 2012-06-06
US20090105244A1 (en) 2009-04-23
DK1807434T3 (da) 2010-11-22
EP1807434B1 (en) 2010-08-25
CA2583550A1 (en) 2006-05-04
ATE478876T1 (de) 2010-09-15
WO2006047124A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
CY1111477T1 (el) Θειενοπυριδινες ως αλλοστερικοι ενισχυτες του μ4 μουσκαρινικου υποδοχεα
ATE454372T1 (de) Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
GEP20084527B (en) Benzimidazolone compounds having 5-ht4 receptor agonistic activity
WO2008077557A8 (en) 8-ethinylxanthine derivatives as selective a2a receptor antagonists
ATE399770T1 (de) Tachykininrezeptorantagonisten
DK1807072T3 (da) Cycloalkyllactamderivater som inhibitorer af 11-beta-hydroxysteroid-dehydrogenase 1
IL179599A0 (en) Glucagon receptor antagonists, preparation and therapeutic uses
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
TW200800943A (en) Indane derivatives as MCH receptor antagonists
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
UA83868C2 (ru) Производные бензимидазолона и хиназолинона в качестве агонистов человеческих рецепторов orl1
ECSP088939A (es) Carboxamidas sustituidas como antagonistas del receptor metabotropico del grupo i
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
BRPI0514579A (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto e gaboxadol, e, processo para preparo de um composto
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
CY1110453T1 (el) Αναστολεις υποδοχεα η3 ισταμινης, παρασκευη και θεραπευτικες χρησεις
PL1853232T3 (pl) Trwałe postaci krystaliczne mesylanu bifeprunoksu, postaci dawkowania oraz sposoby ich stosowania
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
DK1861360T3 (da) Pyrrolidin-derivater som histamin-H3-receptorantagonister
ATE523488T1 (de) Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung
MX2009006346A (es) Derivados de 8-etinilxantina como antagonistas de receptores de a2a selectivos.
MX2007005824A (es) Agonistas y antagonistas del receptor de somatostatina.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2328 DE 18-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.